Yoko Tsukita

Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.

T. Harada, M. Ichinose, T. Nakagawa, 2019, Lung Cancer.

Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.

Y. Hosomi, Y. Kogure, S. Nomura, 2024, Clinical lung cancer.

Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice

K. Takeda, N. Kadoya, K. Jingu, 2022, BMC Cancer.

Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancer

K. Takeda, N. Kadoya, K. Jingu, 2022, PloS one.

Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: a multi-center retrospective study.

K. Jingu, J. Uchida, T. Kodaira, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5

N. Tanaka, T. Okazaki, S. Ebihara, 2018, Oncoimmunology.

Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.

J. Sugisaka, T. Tozuka, H. Asahina, 2024, JAMA oncology.

Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).

T. Yokoyama, M. Tamiya, T. Sakagami, 2023, Lung cancer.